The company’s success stemmed from a jump in the sale of its da Vinci surgical systems, which provide robotic assistance to surgeons
Showing 25 of 5343
The biopharmaceutical company is making great strides toward developing its non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex
US’s largest health insurer is the best performer on the Dow Jones Industrial average
The company reported revenue growth of 173%, hitting $12.9 million in fiscal Q3 2018, up from $4.7 million in the same period last year.
The biotech's experimental drug ZX008 reduced the frequency of convulsive seizures in Phase 3 trial
BioCryst shareholders voted overwhelmingly to torpedo the deal
The Phase 3 double-blind study found that the drug was able to lower the rate of transfusions needed
The company said it has approved a restructuring plan to reduce operating costs and better align the company's workforce with the needs of its business.
Fear of share dilution follows FDA approval of the company's GammaTile therapy for recurrent brain tumors
Leah Rush Cann, a widely-followed analyst with Oppenheimer, is still keeping her Outperform rating on CTI BioPharma, but cutting her stock price target to US$6 from US$7
The deal is with the Sandoz Inc division is for the Adamis’ Symjepi product
ARISTADA INITIO is expected to hit the market later this month
TRV250 is a biased delta receptor that has the potential to be a non-narcotic method for treating migraines
Shares were down 83.8% Wednesday after the Vancouver-based company announced its Phase 3 LEADERSHIP 301 clinical trial aimed at helping patients with cystitis/bladder pain did not meet its end goal.
The AIM-listed pharmaceuticals group said that because of the outcome, it is discontinuing its development of ezutromid and as a result, will be implementing cost reduction measures
The company is making 6.1mln shares available but no other terms were disclosed
The thinly traded shares have spiked in recent days with a big surge in volume
The company said the funds will be used for research and development programs and for general working capital purposes.
Results were delivered at the 2018 Society of Nuclear Medicine and Molecular Imaging Annual meeting
The device uses an algorithm to predict glucose levels 30 minutes into the future
But the dental division saw an 11% dip in revenue
Proceeds of the financing will be used to expand operations and sales in the US, Canada and Europe.
Valeant has requested a meeting with the FDA and is working to overturn its decision
Merck's lung cancer-fighting drug Keytruda has just been approved for the treatment of cervical cancer
Hartaj Singh expects the cancer specialist's two AKT inhibitors to each account for US$3 per share of ArQule's valuation